These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. Early long-term administration of the CSF1R inhibitor PLX3397 ablates microglia and reduces accumulation of intraneuronal amyloid, neuritic plaque deposition and pre-fibrillar oligomers in 5XFAD mouse model of Alzheimer's disease. Sosna J; Philipp S; Albay R; Reyes-Ruiz JM; Baglietto-Vargas D; LaFerla FM; Glabe CG Mol Neurodegener; 2018 Mar; 13(1):11. PubMed ID: 29490706 [TBL] [Abstract][Full Text] [Related]
49. Pathological Changes in Alzheimer's Disease Analyzed Using Induced Pluripotent Stem Cell-Derived Human Microglia-Like Cells. Xu M; Zhang L; Liu G; Jiang N; Zhou W; Zhang Y J Alzheimers Dis; 2019; 67(1):357-368. PubMed ID: 30562902 [TBL] [Abstract][Full Text] [Related]
50. Clearance of cerebral Aβ in Alzheimer's disease: reassessing the role of microglia and monocytes. Zuroff L; Daley D; Black KL; Koronyo-Hamaoui M Cell Mol Life Sci; 2017 Jun; 74(12):2167-2201. PubMed ID: 28197669 [TBL] [Abstract][Full Text] [Related]
51. Microglia in Alzheimer's Disease: The Role of Stem Cell-Microglia Interaction in Brain Homeostasis. Bagheri-Mohammadi S Neurochem Res; 2021 Feb; 46(2):141-148. PubMed ID: 33174075 [TBL] [Abstract][Full Text] [Related]
53. Microglial genes regulating neuroinflammation in the progression of Alzheimer's disease. Villegas-Llerena C; Phillips A; Garcia-Reitboeck P; Hardy J; Pocock JM Curr Opin Neurobiol; 2016 Feb; 36():74-81. PubMed ID: 26517285 [TBL] [Abstract][Full Text] [Related]
54. Modulation of SPARC/Hevin Proteins in Alzheimer's Disease Brain Injury. Strunz M; Jarrell JT; Cohen DS; Rosin ER; Vanderburg CR; Huang X J Alzheimers Dis; 2019; 68(2):695-710. PubMed ID: 30883351 [TBL] [Abstract][Full Text] [Related]
55. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice. Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771 [TBL] [Abstract][Full Text] [Related]
56. Amelioration of amyloid-β-induced deficits by DcR3 in an Alzheimer's disease model. Liu YL; Chen WT; Lin YY; Lu PH; Hsieh SL; Cheng IH Mol Neurodegener; 2017 Apr; 12(1):30. PubMed ID: 28438208 [TBL] [Abstract][Full Text] [Related]
57. Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist. Ardestani PM; Evans AK; Yi B; Nguyen T; Coutellier L; Shamloo M Neuropharmacology; 2017 Apr; 116():371-386. PubMed ID: 28089846 [TBL] [Abstract][Full Text] [Related]
58. Modeling Cellular Crosstalk of Neuroinflammation Axis by Tri-cultures of iPSC-Derived Human Microglia, Astrocytes, and Neurons. Connolly K; Lehoux M; Assetta B; Huang YA Methods Mol Biol; 2023; 2683():79-87. PubMed ID: 37300768 [TBL] [Abstract][Full Text] [Related]
59. The role of inflammation in Alzheimer's disease. Tuppo EE; Arias HR Int J Biochem Cell Biol; 2005 Feb; 37(2):289-305. PubMed ID: 15474976 [TBL] [Abstract][Full Text] [Related]
60. Soluble CCL5 derived from bone marrow-derived mesenchymal stem cells and activated by amyloid β ameliorates Alzheimer's disease in mice by recruiting bone marrow-induced microglia immune responses. Lee JK; Schuchman EH; Jin HK; Bae JS Stem Cells; 2012 Jul; 30(7):1544-55. PubMed ID: 22570192 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]